Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.
A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
GuruFocus does not calculate Inoviq's interest coverage with the available data.
Inoviq's debt to revenue ratio for the quarter that ended in Dec. 2025 was 0.59.
As of today, Inoviq's Altman Z-Score is 3.93.
The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Inoviq has the Financial Strength Rank of 6.
Inoviq Financial Strength Related Terms
ASX:IIQ vs TMO, DHR, IDXX: Financial Strength Comparison
For the Diagnostics & Research subindustry, Inoviq's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inoviq Financial Strength vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inoviq's Financial Strength distribution charts can be found below:
* The bar in red indicates where Inoviq's Financial Strength falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Inoviq has a Z-score of 3.93, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 3.93 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inoviq (ASX:IIQ) has a Financial Strength of 6 as of Dec. 2025. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Inoviq and its competitors. This is 14% below median its historical median of 7.00. Over the past decade, Inoviq's Financial Strength has ranged from 5.00 to 7.00.
Is Inoviq's Financial Strength too high?
Inoviq's current Financial Strength of 6 is 14% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 7.00. Overall, Inoviq has a GF Score™ of 14/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Inoviq's Financial Strength compare to TMO and DHR?
Inoviq's Financial Strength of 6 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Inoviq's own Financial Strength has ranged from 5.00 to 7.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Medical Diagnostics & Research company?
A good Financial Strength depends on the Medical Diagnostics & Research industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Inoviq and its competitors. Inoviq's current Financial Strength is 6, which is 14% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inoviq stock overvalued right now?
Based on GuruFocus' analysis, Inoviq (ASX:IIQ) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.52, compared to a current price of A$0.20 — trading 62.5% below its estimated fair value. The current Financial Strength is 6, which is 14% below median its 10-year median of 7.00. Inoviq's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For Inoviq (ASX:IIQ), the current Financial Strength is 6 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inoviq (ASX:IIQ) Overvalued in 2026?
Based on GuruFocus' analysis, Inoviq stock appears to be undervalued.
The current stock price of A$0.20 is trading 62.5% below its estimated GF Value™ of A$0.52.
GuruFocus considers Inoviq to be Possible Value Trap.
Key valuation signals for ASX:IIQ:
Financial Strength: 6 (14% below median its 10-year median of 7.00)
GF Value™: A$0.52 vs. price of A$0.20 (62.5% below fair value)
No single metric tells the full story. See the ASX:IIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.
14GF Score
Get the complete analysis for ASX:IIQ
Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IIQ has been successfully added to your 
